Novo Nordisk stock: does oral Wegovy approval make it better pick than Eli Lilly?

Core Viewpoint - HSBC's senior research analyst Rajesh Kumar suggests that Novo Nordisk may have a competitive advantage over Eli Lilly as they approach 2026 [1] Company Analysis - Novo Nordisk is positioned favorably in the market compared to Eli Lilly, according to recent insights from HSBC [1] - The analysis indicates that Novo Nordisk's strategies and product offerings could lead to enhanced performance in the coming years [1] Industry Context - The pharmaceutical industry is witnessing intense competition, particularly in the diabetes and obesity treatment segments, where both Novo Nordisk and Eli Lilly operate [1] - The insights provided by HSBC reflect broader trends in the industry, emphasizing the importance of innovation and market positioning [1]